Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Neurobiol Aging. 2013 Apr 30;34(10):2421–2430. doi: 10.1016/j.neurobiolaging.2013.04.002

Fig. 7. Reduction of amyloid precursor protein (APP) levels in the brain after treatment with tolfenamic acid.

Fig. 7

Tolfenamic acid was administered by oral gavage daily for 34 days. See the methods section for details. A) Western blot analysis of cortical APP levels as a ratio of the house keeping protein β-actin after treatment with 5 and 50 mg/kg/day of tolfenamic acid for 34 days; B) Cortical APP mRNA determined by Real-Time PCR. “*” Indicates that values are significantly different from vehicle, as determined by one-way ANOVA analysis with Tukey-Kramer post-hoc test to compare all pairs of columns (p<0.05), obtained using GraphPad InStat 3 software.